Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):VED
АТХ:V.09.D.A Compounds of technetium 99m
Pharmacodynamics:Diagnostic tool, radiopharmaceuticalIt allows to assess the functional state of the hepatobiliary system under its various pathological conditions.
Pharmacokinetics:The drug 99mTc after intravenous administration is absorbed by polygonal cells of the liver and in the bile is excreted into the intestine, where it is not reabsorbed. High concentration of the drug in the liver, biliary tract and gallbladder allows you to visualize the liver, gallbladder, intra- and extrahepatic bile ducts.
In hepatocytes, the maximum accumulation time is 7-13 minutes; the half-life of liver parenchyma is 19-30 minutes; time of appearance in the gallbladder 4-8 minutes; TCmax - 25-40 minutes; Tlat 1-9 minutes. The maximum content of the drug in the liver and biliary tract in a patient without functional or organic changes is about 70% of the administered amount. In this case, urine excreted about 1% within 3 hours after administration. With bilirubinemia, the accumulation of the drug in the liver decreases, and its excretion in the urine increases.
Indications:As a diagnostic tool in adults for radionuclide hepatocholecystraffia in diseases of the liver, gall bladder, biliary tract, jaundice of various etiologies and other pancreatoduodenal lesionszone.
XXI.Z00-Z13.Z03 Medical surveillance and evaluation in case of suspected disease or pathological condition
Contraindications:- pregnancy and lactation;
- hypersensitivity to the drug or its components.
Pregnancy and lactation:The use is contraindicated.
Dosing and Administration:Enter intravenously immediately before the test.
The injected dose: 1.1 MBq per 1 kg of body weight (not less than 10 mg of the basic substance) with normal bilirubin content in the blood. In patients with hyperbilirubinemia, the amounts of activity and basic substance administered should be increased to 3.7-5.5 MBq / kg and 20-40 mg, respectively.
Side effects:Side effects with the use of the drug for diagnostic purposes are not revealed.
Overdose:With a single injection, an overdose is unlikely, due to the lack of pharmacodynamicproperties.
Interaction:The concomitant use of cholagogue funds leads to an acceleration of the transit of the drug through the hepatobiliary system.
Special instructions:Work with the drug should be carried out in accordance with the "Basic Sanitary Rules for Ensuring Radiation Safety" (OSPORB-99), "Radiation Safety Standards" (NRB-99) and guidelines "Hygienic requirements for ensuring radiation safety during radionuclide diagnostics using radiopharmaceuticals "(MU 2.6.1.1892-04).
Can be used at a level of bilirubin in the blood above 150 μmol / l.
Implementation through the pharmacy network is not. It is only released on request-applications to specialized radioisotope laboratories of medical diagnostic facilities.